Express News | Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Moomoo 24/7Apr 19 16:43 ET
Express News | Gilead Sciences, Inc Reports 13.9% Passive Stake in Leap Therapeutics as of April 10- SEC Filing
Moomoo 24/7Apr 19 16:33 ET
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Seeking AlphaApr 12 11:34 ET
Express News | Leap Therapeutics Shares Are Trading Higher After the Company Announced a $40 Million Private Placement
Moomoo 24/7Apr 11 09:16 ET
Express News | Leap Therapeutics Inc: Intends to Use Net Proceeds From Financing to Fund Continued Development of Its Lead Monoclonal Antibody Program, Dkn-01
Moomoo 24/7Apr 11 08:31 ET
Express News | Leap Therapeutics : Net Proceeds, Along With Existing Cash, Cash Equivalents, & Marketable Securities Are Expected to Extend Cash Runway Into Q2 2026
Moomoo 24/7Apr 11 08:30 ET
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme
Leap TherapeuticsApr 11 00:00 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million. Leap Thera
BenzingaMar 20 17:34 ET
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Leap Therapeutics (LPTX) has an average outperform rating and price target range of $7 to $16, according to analysts polled by Capital IQ.
MT NewswiresMar 19 09:30 ET
Leap Therapeutics Is Maintained at Outperform by Baird
Leap Therapeutics Is Maintained at Outperform by Baird
Dow JonesMar 19 07:20 ET
Express News | Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Moomoo 24/7Mar 19 07:09 ET
Express News | HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $7 Price Target
Moomoo 24/7Mar 19 06:48 ET
Leap Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/19/2024 216.74% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/20/2023 442.99% Mizuho $20 → $12 Maint
BenzingaMar 19 06:46 ET
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
TipRanksMar 19 06:19 ET
Leap Therapeutics' Success Tied to Partner NovaRock's Commitment in Asian Markets
TipRanksMar 19 02:00 ET
Leap Therapeutics: Q4 Earnings Insights
Leap Therapeutics (NASDAQ:LPTX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsLeap Therapeutics beat estimate
BenzingaMar 18 11:10 ET
Leap Therapeutics Files for $200M Mixed Shelf Offering
Seeking AlphaMar 18 10:56 ET
Leap Therapeutics GAAP EPS of -$0.46 Beats by $0.10
Seeking AlphaMar 18 07:10 ET
Leap Therapeutics 4Q Loss/Shr 46c >LPTX
Leap Therapeutics 4Q Loss/Shr 46c >LPTX
Dow JonesMar 18 07:00 ET
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Leap Therapeutics (LPTX)
TipRanksJan 26 00:42 ET
No Data
No Data